Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1420306

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1420306

Biobetters Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED:
PAGES: 242 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The global Biobetters Market has demonstrated robust growth from 2024 to 2031. This growth trajectory is set to continue, with an anticipated steady CAGR of 10% expected between 2024 and 2031. In 2024, the global Biobetters Market reached a size of US$ 60 billion, and it is projected to attain a valuation of US$ 115 billion by 2031.

Overview of the Biobetters Market

Biobetters, also known as biosuperiors, represent a class of recombinant protein drugs that belong to the same category as existing biopharmaceuticals. However, they are distinct in that they are not identical to the source drugs. Biobetters are designed to enhance clinical efficacy, improve tolerance, reduce dosing frequency, and lower side effects. The Biobetters Market is poised to grow due to their numerous advantages, including superior therapeutic efficacy, reduced side effects, cost-effective production methods, non-patent and market exclusivity, extended product half-life, reduced dosage frequency, and attractive investment opportunities.

Factors Driving the Growth of the Biobetters Market

"High Efficacy and Few Side Effects"

Biobetters are engineered to be improved versions of existing biologics, offering enhanced therapeutic benefits, reduced side effects, and less frequent dosing. This superior efficacy and lower dosing frequency contribute to patient compliance and are expected to drive significant market growth.

"Simple and Cost-effective Manufacturing Process"

Biobetters are manufactured using processes similar to biologics, with the incorporation of modern technologies such as pegylation and albumin replacement. These techniques have streamlined the production of biobetters, making it more cost-effective compared to biologics. Biobetters have a shorter development timeline, approximately 10 years, in contrast to the longer development period of around 15 years for biologics. While biosimilars require roughly half the development cost of biobetters, the latter offer superior therapeutic effectiveness.

"Increasing Research Activities"

Continuous research efforts by biopharmaceutical manufacturers and investors to develop improved formulations are driving the expansion of the biobetters market. Advanced biophysical and biochemical approaches have emerged, providing significant momentum to the industry's growth.

"Increased Investment in Developing Therapeutic Agents"

The growing investment in developing therapeutic agents with enhanced effectiveness and safety profiles for conditions such as cancers and autoimmune diseases is influencing the biobetters market positively. Efforts to mitigate the economic impact of chronic diseases have led to substantial investments in new drug development, further fueling market growth.

Challenges Faced by the Biobetters Market

"High Investments Required for R&D Activities"

The development of novel medicinal drugs, including biobetters, demands substantial investments in research and development, which can act as a limitation on market growth. However, the post-COVID-19 era has witnessed a significant surge in R&D spending for the development of biobetters. Additionally, increasing biosimilar competition poses challenges to market expansion.

Impact of COVID-19 on the Biobetters Market

"Increase in Investment for Developing Novel Biobetters"

The COVID-19 pandemic has prompted a notable increase in R&D investment for the development of novel biobetters. Manufacturers and investors in the biobetter industry are actively working on improving formulations, resulting in numerous novel medications in the pipeline or undergoing clinical trials.

Competitive Landscape

The Biobetters market is characterized by intense competition, with several major players dominating the industry. Market participants are focusing on mergers and strategic alliances to expand their product portfolios and enhance market share, leveraging the industry's growth phase.

Key Companies Profiled

  • F.Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Sanofi SA
  • SERVIER
  • Porton Biopharma Limited
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Biogen Inc.
  • CSL Behring GmbH
  • Teva Pharmaceutical Industries Ltd.

Biobetters Market Segmentation

Biobetters Market by By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Biobetters Market By Molecule Type

  • G-CSF Biobetters
  • Insulin Biobetters
  • Erythropoietin Biobetters
  • Monoclonal Antibodies Biobetters
  • Others

Biobetters Market by Disease Indication

  • Cancer
  • Diabetes
  • Genetic disease
  • Neurological Disorders
  • Others

Biobetters Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Biobetters Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Biobetters Market Outlook, 2018 - 2031

  • 3.1. Global Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Erythropoietin Biobetters
      • 3.1.1.2. G-CSF Biobetters
      • 3.1.1.3. Interferon Biobetters
      • 3.1.1.4. Insulin Biobetters
      • 3.1.1.5. Monoclonal Antibodies Biobetters
      • 3.1.1.6. Anti-haemophilic Factor
      • 3.1.1.7. Others
  • 3.2. Global Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Diabetes
      • 3.2.1.2. Cancer
      • 3.2.1.3. Renal Disease
      • 3.2.1.4. Neurodegenerative Disease
      • 3.2.1.5. Genetic Disorders (Haemophilia)
      • 3.2.1.6. Others
  • 3.3. Global Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Subcutaneous
      • 3.3.1.2. Intravenous
  • 3.4. Global Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Online Pharmacies
  • 3.5. Global Biobetters Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Biobetters Market Outlook, 2018 - 2031

  • 4.1. North America Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Erythropoietin Biobetters
      • 4.1.1.2. G-CSF Biobetters
      • 4.1.1.3. Interferon Biobetters
      • 4.1.1.4. Insulin Biobetters
      • 4.1.1.5. Monoclonal Antibodies Biobetters
      • 4.1.1.6. Anti-haemophilic Factor
      • 4.1.1.7. Others
  • 4.2. North America Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Diabetes
      • 4.2.1.2. Cancer
      • 4.2.1.3. Renal Disease
      • 4.2.1.4. Neurodegenerative Disease
      • 4.2.1.5. Genetic Disorders (Haemophilia)
      • 4.2.1.6. Others
  • 4.3. North America Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Subcutaneous
      • 4.3.1.2. Intravenous
  • 4.4. North America Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Online Pharmacies
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.2. U.S. Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.3. U.S. Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.5.1.4. U.S. Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.5.1.5. Canada Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.6. Canada Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.7. Canada Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.5.1.8. Canada Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Biobetters Market Outlook, 2018 - 2031

  • 5.1. Europe Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Erythropoietin Biobetters
      • 5.1.1.2. G-CSF Biobetters
      • 5.1.1.3. Interferon Biobetters
      • 5.1.1.4. Insulin Biobetters
      • 5.1.1.5. Monoclonal Antibodies Biobetters
      • 5.1.1.6. Anti-haemophilic Factor
      • 5.1.1.7. Others
  • 5.2. Europe Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Diabetes
      • 5.2.1.2. Cancer
      • 5.2.1.3. Renal Disease
      • 5.2.1.4. Neurodegenerative Disease
      • 5.2.1.5. Genetic Disorders (Haemophilia)
      • 5.2.1.6. Others
  • 5.3. Europe Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Subcutaneous
      • 5.3.1.2. Intravenous
  • 5.4. Europe Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Online Pharmacies
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.2. Germany Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.3. Germany Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.4. Germany Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.5. U.K. Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.6. U.K. Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.7. U.K. Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.8. U.K. Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.9. France Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.10. France Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.11. France Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.12. France Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.13. Italy Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.14. Italy Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.15. Italy Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.16. Italy Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.17. Turkey Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.18. Turkey Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.19. Turkey Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.20. Turkey Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.21. Russia Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.22. Russia Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.23. Russia Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.24. Russia Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Biobetters Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Erythropoietin Biobetters
      • 6.1.1.2. G-CSF Biobetters
      • 6.1.1.3. Interferon Biobetters
      • 6.1.1.4. Insulin Biobetters
      • 6.1.1.5. Monoclonal Antibodies Biobetters
      • 6.1.1.6. Anti-haemophilic Factor
      • 6.1.1.7. Others
  • 6.2. Asia Pacific Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Diabetes
      • 6.2.1.2. Cancer
      • 6.2.1.3. Renal Disease
      • 6.2.1.4. Neurodegenerative Disease
      • 6.2.1.5. Genetic Disorders (Haemophilia)
      • 6.2.1.6. Others
  • 6.3. Asia Pacific Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Subcutaneous
      • 6.3.1.2. Intravenous
  • 6.4. Asia Pacific Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Online Pharmacies
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.2. China Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.3. China Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.4. China Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.5. Japan Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.6. Japan Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.7. Japan Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.8. Japan Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.9. South Korea Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.10. South Korea Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.11. South Korea Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.12. South Korea Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.13. India Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.14. India Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.15. India Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.16. India Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Biobetters Market Outlook, 2018 - 2031

  • 7.1. Latin America Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Erythropoietin Biobetters
      • 7.1.1.2. G-CSF Biobetters
      • 7.1.1.3. Interferon Biobetters
      • 7.1.1.4. Insulin Biobetters
      • 7.1.1.5. Monoclonal Antibodies Biobetters
      • 7.1.1.6. Anti-haemophilic Factor
      • 7.1.1.7. Others
  • 7.2. Latin America Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Diabetes
      • 7.2.1.2. Cancer
      • 7.2.1.3. Renal Disease
      • 7.2.1.4. Neurodegenerative Disease
      • 7.2.1.5. Genetic Disorders (Haemophilia)
      • 7.2.1.6. Others
  • 7.3. Latin America Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Subcutaneous
      • 7.3.1.2. Intravenous
  • 7.4. Latin America Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Online Pharmacies
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.2. Brazil Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.3. Brazil Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.4. Brazil Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.5. Mexico Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.6. Mexico Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.7. Mexico Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.8. Mexico Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.9. Argentina Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.10. Argentina Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.11. Argentina Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.12. Argentina Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Biobetters Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Erythropoietin Biobetters
      • 8.1.1.2. G-CSF Biobetters
      • 8.1.1.3. Interferon Biobetters
      • 8.1.1.4. Insulin Biobetters
      • 8.1.1.5. Monoclonal Antibodies Biobetters
      • 8.1.1.6. Anti-haemophilic Factor
      • 8.1.1.7. Others
  • 8.2. Middle East & Africa Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Diabetes
      • 8.2.1.2. Cancer
      • 8.2.1.3. Renal Disease
      • 8.2.1.4. Neurodegenerative Disease
      • 8.2.1.5. Genetic Disorders (Haemophilia)
      • 8.2.1.6. Others
  • 8.3. Middle East & Africa Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Subcutaneous
      • 8.3.1.2. Intravenous
  • 8.4. Middle East & Africa Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Online Pharmacies
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.2. GCC Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.3. GCC Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.4. GCC Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.5. South Africa Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.6. South Africa Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.7. South Africa Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.8. South Africa Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.9. Egypt Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.10. Egypt Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.11. Egypt Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.12. Egypt Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.13. Nigeria Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.14. Nigeria Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.15. Nigeria Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.16. Nigeria Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Product vs Indication Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. F.Hoffmann-La Roche AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Merck & Co. Inc.
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Sanofi SA
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. SERVIER
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Porton Biopharma Limited
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Eli Lily and Company
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Novo Nordisk A/S
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Biogen Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. CSL Behring GmbH
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Teva Pharmaceutical Industries Ltd.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!